DataMeds AI, Inc. (MEDS) company profile
Close on Nov 17, 2026Market cap $1.96MP/E –Yield –
About DataMeds AI
Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122
Wellgistics Health, Inc. operates as a healthcare and pharmaceutical holding company providing integrated solutions across dispensing, delivery, care coordination, and clinical management. Its business model spans three primary operating segments: a retail specialty pharmacy, pharmaceutical wholesale operations, and a technology division. The company's offerings include distribution of specialty-lite and maintenance medications, clinical concierge support, and digital prescription transfer services. Wellgistics serves individual patients, independent pharmacies, healthcare providers, pharmaceutical manufacturers, and health payors.
The company operates through wholly owned operating subsidiaries, including Wellgistics, LLC and Wood Sage LLC, distributing niche pharmaceuticals to a nationwide network of independent pharmacy partners across the United States. Its retail pharmacy operations originate from a facility established in Florida. Wellgistics Health maintains its principal executive offices in Tampa, Florida.
Summary of the business section of DataMeds AI's latest annual report, written by StockData.
Company profile
Company
- Legal name
- DataMeds AI, Inc.
- Founded
- 2022
- Headquarters
- Tampa, FL
- Address
- 3000 Bayport Drive Suite 950 33607
- Phone
- 1-843-302-1785
- Website
- datamedsai.com
- Employees
- 35, Dec 31, 2025
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Suri & Co., Chartered Accountants, Bengaluru, India
Stock & identifiers
- Ticker
- MEDS
- Former tickers
- WGRX until Jul 29, 2026
- Exchange
- Nasdaq
- IPO date
- Feb 21, 2025
- Shares outstanding
- 3M, Aug 17, 2026
- Public float
- $27.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-50 reverse, May 26, 2026
- SEC CIK
- 2030763
- CUSIP
- 949503205
- ISIN
- US9495032057
- FIGI
- BBG01LG7MTZ3
- Share class FIGI
- BBG01LG7MV06
- EIN
- 93-3264234
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Prashant Patel | Chief Executive Officer, Director | 9,354,365 |
| Srinivas Kalla | Chief Information Officer | 293,333 |
| Mark DiSiena | Chief Financial Officer | – |
| Brian Norton | Chief Executive Officer | 11,524,308 |
| Nikul Panchal | Chief Pharmacy Officer | 375,761 |
| Shafaat Pirani | Chief Clinical Officer | 102,080 |
| Surendra K. Ajjarapu | Director | 15,445,447 |
| Gary L. Herman | Director | – |
| Eric Michael Sherb | Director | – |
| Marlene Velez | Director | – |
| Howard A. Doss | Director | – |
| Donald G. Fell | Director | – |
| Steven Dale Lee | Director | – |
| Michael L. Peterson | Director | 200,000 |
| Donald William Anderson | Director | 244,720 |
| Rebecca M. Shanahan | Director | 244,720 |
| Sajid Syed | Director | 244,720 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 21, 2025
- Offer price
- $4.50
- Securities offered
- 888,889
- Gross proceeds
- $4.00M
- Exchange
- Nasdaq
- First trading day
- Feb 21, 2025
- First-day close
- $3.81-15.3%
- Lock-up ends (est.)
- Aug 20, 2025
“The initial public offering price of our shares of Common Stock is $4.50 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“● loss of key employees of the acquired businesses following the acquisition; and … 35”
Corporate history
Events identified from SEC filings
See a number that looks wrong?